Inovio Pharmaceuticals Inc (INO) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) in a research report released on Sunday, May 28th. They currently have a $13.00 target price on the biopharmaceutical company’s stock.

Several other brokerages have also weighed in on INO. Stifel Nicolaus reiterated a buy rating and set a $11.00 price objective on shares of Inovio Pharmaceuticals in a report on Thursday, May 25th. Aegis raised their price target on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the stock a buy rating in a research report on Thursday, May 25th. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, May 15th. Maxim Group raised their price target on shares of Inovio Pharmaceuticals from $10.00 to $12.00 and gave the stock a buy rating in a research report on Wednesday, May 24th. Finally, Piper Jaffray Companies downgraded shares of Inovio Pharmaceuticals from an overweight rating to a neutral rating and decreased their price objective for the stock from $13.00 to $9.00 in a report on Thursday, March 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $19.57.

Inovio Pharmaceuticals (NASDAQ INO) traded up 1.91% on Friday, hitting $7.99. 820,625 shares of the company were exchanged. The firm’s 50 day moving average is $7.30 and its 200 day moving average is $6.82. The company’s market capitalization is $596.27 million. Inovio Pharmaceuticals has a 52 week low of $5.83 and a 52 week high of $11.61.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.31). Inovio Pharmaceuticals had a negative net margin of 222.49% and a negative return on equity of 81.23%. The company had revenue of $10.40 million for the quarter, compared to analysts’ expectations of $5.83 million. During the same period last year, the company earned ($0.11) EPS. The firm’s revenue for the quarter was up 28.4% compared to the same quarter last year. On average, equities research analysts forecast that Inovio Pharmaceuticals will post ($1.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Inovio Pharmaceuticals Inc (INO) Rating Reiterated by HC Wainwright” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/hc-wainwright-reiterates-buy-rating-for-inovio-pharmaceuticals-inc-ino-updated-updated/862511.html.

In other news, CEO Jong Joseph Kim sold 147,180 shares of Inovio Pharmaceuticals stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $6.54, for a total transaction of $962,557.20. Following the completion of the sale, the chief executive officer now directly owns 2,164,887 shares in the company, valued at approximately $14,158,360.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David B. Weiner sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the completion of the sale, the director now owns 740,956 shares of the company’s stock, valued at $5,927,648. The disclosure for this sale can be found here. Insiders own 10.60% of the company’s stock.

Large investors have recently bought and sold shares of the company. Credit Suisse AG raised its stake in Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 69,068 shares during the period. Metropolitan Life Insurance Co. NY raised its stake in Inovio Pharmaceuticals by 8.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 4,020 shares during the period. Bank of America Corp DE raised its stake in Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 3,605 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Inovio Pharmaceuticals by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 305,844 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 16,845 shares during the period. Finally, Geode Capital Management LLC raised its stake in Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock valued at $3,708,000 after buying an additional 62,045 shares during the period. Hedge funds and other institutional investors own 27.73% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with our FREE daily email newsletter.

 


Latest News

Hitters in Major League Baseball on Record Home Run Pace
Hitters in Major League Baseball on Record Home Run Pace
Atlanta Considering Playing Freddie Freeman at Third
Atlanta Considering Playing Freddie Freeman at Third
Injury to Gleyber Torres Adds to Questions About Yankees
Injury to Gleyber Torres Adds to Questions About Yankees
Game Winning Home Run Completes Nolan Arenado Cycle
Game Winning Home Run Completes Nolan Arenado Cycle
New York Yankees and Masahiro Tanaka Hit Hard Again
New York Yankees and Masahiro Tanaka Hit Hard Again
Victor Martinez Diagnosed with Irregular Heartbeat
Victor Martinez Diagnosed with Irregular Heartbeat


Leave a Reply

 
© 2006-2017 BBNS.